Pomalidomide 4'-PEG2-acid is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Its structure allows for the conjugation of pomalidomide, an immunomodulatory drug, to antibodies via a polyethylene glycol (PEG) linker. This enhances the drug's solubility and stability, while enabling precise delivery to cancer cells. The PEG spacer improves pharmacokinetics, reducing off-target effects and increasing therapeutic efficacy. It is particularly valuable in treating hematologic malignancies like multiple myeloma, where targeted delivery minimizes damage to healthy tissues. The compound is also explored in research for its potential in modulating the tumor microenvironment and enhancing immune response against cancer cells.